UNSPSC 51123300: Antiarrythmic azocines

This classification denotes compounds based on C7H7N or azacyclooctatetraene, called azocines, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC AZOCINES.

UNSPSC 51123300 Antiarrhythmic azocines, a Class code, covers emergency cardiac medications supplied to municipal fire and rescue services, state health agencies, and multistate cooperative purchasing entities. State and local governments procure specific antiarrhythmic drugs — such as adenosine, diltiazem, and epinephrine formulations — for advanced life support programs operated by emergency medical services and hospital systems. Solicitations require vendors to meet strict pharmaceutical compliance standards including FDA certification, Good Manufacturing Practices compliance, Drug Supply Chain Security Act adherence, Safety Data Sheets documentation, and expiration-date guarantees of nine months to one year from delivery. Buying bodies span city purchasing departments managing fire rescue operations, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement across member jurisdictions. The code sees activity from municipal emergency services in Florida, state-level health programs in Texas, and regional cooperative purchasing vehicles such as MMCAP serving multiple states including Minnesota and Oregon.

Recent opportunities show Tampa Fire Rescue procuring adenosine, diltiazem, epinephrine, and labetalol through the City of Tampa's Purchasing Department via sealed-bid IFB (Solicitation 26P00188, due April 8, 2026, estimated value $40,000.00), with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to explore direct-to-manufacturer prescription programs and vendor capabilities for fulfilling antiarrhythmic and broader pharmacy needs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, proposals due March 26, 2026), requiring vendors to maintain relationships with three authorized wholesalers and meet price-competitiveness weighting of 75 percent, with contract start July 1, 2026. Vendors must provide comprehensive product data including National Drug Codes, comply with insurance requirements up to $5 million per occurrence, and accept performance penalties of $200 to $1,500 per violation for reporting or onboarding failures.